Applying Enhanced Understanding of the Mechanisms of Disease in Generalized Myasthenia Gravis (gMG): Improved Diagnostics and Targeted Treatment Options

CME: 1.0

March 9, 2021
KEYWORDS Primary Care
/ Print / Reprints /
| Share More
/ Text Size+

Describe the role of pathogenic antibodies in driving the pathophysiology of Generalized Myasthenia Gravis (gMG) their contributions as biomarkers of disease and potential response to therapy, and the need for autoantibody testing

Post a comment to this article